Phase II study of pembrolizumab (MK-3475) in patients with metastatic castration-resistant prostate cancer (KEYNOTE-199)—study AP 93/16 of the AUO

Heidrun Rexer; M. Graefen; A. Merseburger

doi:10.1007/s00120-017-0519-9

Phase II study of pembrolizumab (MK-3475) in patients with metastatic castration-resistant prostate cancer (KEYNOTE-199)—study AP 93/16 of the AUO

Heidrun Rexer
, M. Graefen
, A. Merseburger

Department of Urology

AUO Geschäftsstelle
Organgruppensprecher der Arbeitsgemeinschaft Urologische Onkologie in der Deutschen Krebsgesellschaft e. V.

5 Citations (Scopus)

Original language	English
Journal	Urologe
Volume	56
Issue number	11
Pages (from-to)	1471-1472
Number of pages	2
ISSN	0340-2592
DOIs	https://doi.org/10.1007/s00120-017-0519-9
Publication status	Published - 01.11.2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)

Access to Document

10.1007/s00120-017-0519-9

Cite this

@article{dde718a2063649d9a604ab23f0b78b43,

title = "Phase II study of pembrolizumab (MK-3475) in patients with metastatic castration-resistant prostate cancer (KEYNOTE-199){\textemdash}study AP 93/16 of the AUO",

author = "Heidrun Rexer and M. Graefen and A. Merseburger",

year = "2017",

month = nov,

day = "1",

doi = "10.1007/s00120-017-0519-9",

language = "English",

volume = "56",

pages = "1471--1472",

journal = "Urologe",

issn = "0340-2592",

publisher = "Springer Medizin",

number = "11",

}

TY - JOUR

T1 - Phase II study of pembrolizumab (MK-3475) in patients with metastatic castration-resistant prostate cancer (KEYNOTE-199)—study AP 93/16 of the AUO

AU - Rexer, Heidrun

AU - Graefen, M.

AU - Merseburger, A.

PY - 2017/11/1

Y1 - 2017/11/1

UR - https://www.scopus.com/pages/publications/85030538513

U2 - 10.1007/s00120-017-0519-9

DO - 10.1007/s00120-017-0519-9

M3 - Comments/Debates

C2 - 28980011

AN - SCOPUS:85030538513

SN - 0340-2592

VL - 56

SP - 1471

EP - 1472

JO - Urologe

JF - Urologe

IS - 11

ER -

Phase II study of pembrolizumab (MK-3475) in patients with metastatic castration-resistant prostate cancer (KEYNOTE-199)—study AP 93/16 of the AUO

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Cite this